Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Panic disorder is a debilitating condition with complex neurobiological underpinnings.
• Serotonin (5-HT) neurotransmission is implicated in mood and anxiety disorders, but its precise role in panic disorder remains unclear.
• Specific serotonin receptor subtypes and their functions in panic disorder require further investigation.

Purpose of the Study:

• To evaluate the role of serotonin (5-HT) function in panic disorder.
• To assess the efficacy of a selective 5-HT reuptake inhibitor (fluvoxamine) and a specific 5-HT2 receptor antagonist (ritanserin) in treating panic disorder.
• To investigate biochemical markers of serotonin function in patients with panic disorder.

Main Methods:

• A double-blind, placebo-controlled study was conducted with 60 patients diagnosed with panic disorder.
• Participants received 8 weeks of treatment with either 150 mg of fluvoxamine, 20 mg of ritanserin, or a placebo.
• Biochemical markers including plasma concentrations of beta-endorphin, cortisol, 5-hydroxyindoleacetic-acid (5-HIAA), MHPG, and melatonin were measured. Serotonin (5-HT) uptake in blood platelets was also assessed.

Main Results:

• Fluvoxamine treatment led to a significant reduction in panic attack frequency and subsequent decrease in avoidance behavior.
• Ritanserin treatment did not demonstrate significant efficacy in alleviating panic disorder symptoms.
• While no significant changes were observed in beta-endorphin, cortisol, 5-HIAA, or MHPG levels, fluvoxamine increased plasma melatonin concentrations, suggesting serotonergic control over melatonin synthesis.
• Fluvoxamine altered platelet serotonin (5-HT) kinetics, increasing Km and decreasing Vmax.

Conclusions:

• The findings do not support the hypothesis of 5-HT2 receptor supersensitivity in panic disorder.
• Fluvoxamine's efficacy suggests a role for selective serotonin reuptake inhibition in managing panic disorder.
• The study indicates that melatonin synthesis may be partially regulated by serotonin, offering insights into neuroendocrine-serotonin interactions.
• Further research is needed to explore the involvement of other serotonin receptor subtypes in panic disorder.